ZEALC logo

Zealand Pharma BATS-CHIXE:ZEALC Stock Report

Last Price

DKK 625.50

Market Cap

DKK 37.7b

7D

0%

1Y

-8.9%

Updated

10 Mar, 2025

Data

Company Financials +

Zealand Pharma A/S

BATS-CHIXE:ZEALC Stock Report

Market Cap: DKK 37.7b

ZEALC Stock Overview

A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. More details

ZEALC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Zealand Pharma A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zealand Pharma
Historical stock prices
Current Share PriceDKK 625.50
52 Week HighDKK 953.50
52 Week LowDKK 588.50
Beta0.53
1 Month Change-15.62%
3 Month Change-16.88%
1 Year Change-8.92%
3 Year Changen/a
5 Year Change250.22%
Change since IPO917.07%

Recent News & Updates

Recent updates

Shareholder Returns

ZEALCGB BiotechsGB Market
7D0%-1.1%-2.7%
1Y-8.9%-12.1%8.8%

Return vs Industry: ZEALC exceeded the UK Biotechs industry which returned -11.5% over the past year.

Return vs Market: ZEALC underperformed the UK Market which returned 9.6% over the past year.

Price Volatility

Is ZEALC's price volatile compared to industry and market?
ZEALC volatility
ZEALC Average Weekly Movementn/a
Biotechs Industry Average Movement7.8%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.2%
10% least volatile stocks in GB Market2.7%

Stable Share Price: ZEALC's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine ZEALC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997335Adam Steensbergwww.zealandpharma.com

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Zealand Pharma A/S Fundamentals Summary

How do Zealand Pharma's earnings and revenue compare to its market cap?
ZEALC fundamental statistics
Market capDKK 37.69b
Earnings (TTM)-DKK 1.08b
Revenue (TTM)DKK 62.69m

601.2x

P/S Ratio

-34.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZEALC income statement (TTM)
RevenueDKK 62.69m
Cost of RevenueDKK 7.87m
Gross ProfitDKK 54.82m
Other ExpensesDKK 1.13b
Earnings-DKK 1.08b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 08, 2025

Earnings per share (EPS)-15.27
Gross Margin87.44%
Net Profit Margin-1,720.87%
Debt/Equity Ratio3.3%

How did ZEALC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/10 06:19
End of Day Share Price 2025/03/03 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zealand Pharma A/S is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura HindleyBerenberg
Kerry HolfordBerenberg
Charlie HaywoodBofA Global Research